Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odanacatib vs Zoledronic Acid in Breast Cancer with Bone Metastases
NCT00399802Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2006
- Primary completion
- Dec 2007
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of odanacatib in bone metastasis, sponsored by Merck & Co.. Started Nov 2006; status: completed.
02
Drugs
odanacatib
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT00399802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00399802.